...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus
【24h】

Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus

机译:超分子胰岛素组装体II持续治疗1型糖尿病

获取原文
获取原文并翻译 | 示例
           

摘要

Diabetes is a chronic disease requiring continuous medical supervision and patient education to prevent acute secondary complications. In this study, we have harnessed the inherent property of insulin to aggregate into an oligomeric intermediate on the pathway to amyloid formation, to generate a form that exhibits controlled and sustained release for extended periods. Administration of a single dose of the insulin oligomer, defined here as the supramolecular insulin assembly II (SIA-II), to experimental animals rendered diabetic by streptozotocin or alloxan, released the hormone capable of maintaining physiologic glucose levels for >120 days for bovine and >140 days for recombinant human insulin without fasting hypoglycemia. Moreover, the novel SIA-II described here not only improved the glycemic control, but also reduced the extent of secondary diabetic complications.
机译:糖尿病是一种慢性疾病,需要持续的医学监督和患者教育,以防止急性继发性并发症。在这项研究中,我们利用了胰岛素的固有特性,使其聚集在淀粉样蛋白形成途径上的低聚中间体中,从而生成了可长时间控制释放和持续释放的形式。将单剂量的胰岛素低聚物(此处定义为超分子胰岛素组装体II(SIA-II))给予链脲佐菌素或四氧嘧啶致糖尿病的实验动物,可释放出这种激素,能够维持牛和猪的生理性葡萄糖水平> 120天。没有空腹低血糖的重组人胰岛素> 140天。而且,这里描述的新型SIA-II不仅改善了血糖控制,而且减少了继发性糖尿病并发症的程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号